Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced its decision to cease development of the anti-TIGIT antibody vibostolimab in combination with its anti-PD-1 drug Keytruda (pembrolizumab) as an adjuvant treatment for resected high-risk melanoma. This strategic move follows an interim analysis that failed to meet the primary endpoint of recurrence-free survival (RFS).
The late-stage study was designed to evaluate the efficacy of the vibostolimab and Keytruda combination against Keytruda monotherapy. Although the data analysis continues, MSD is advising that all participants in the trial continue treatment with Keytruda alone, a drug that currently has two melanoma approvals.
As stated in the press release, MSD is persisting in its assessment of the vibostolimab and Keytruda combination for lung cancer.- Flcube.com
